Replies to post #256756 on Biotech Values

[dewophile]

totally expected - as you know phase 2 results in virology translate to phase 3 almost always
Most HBV patients have higher baseline SA levels though but still nice to see the first real advance in this space (INF is de minimis)
PS: I sold the remaining (small) portion of my GSK yesterday when it crossed 50! one day too early although i see the stock not doing all that much on this news (not surprised)

[vinmantoo]

GSK/IONS—Bepirovirsen phase-3 trials hit_primary_endpoint_of HBV functional cure:

Good to see progress being made in Hep B. Still, how much better than standard of care these new data shows. I kept fantasizing that ENTA's Hep B drug EDP-514 would fine a role in a partnership but that remains a pipedream.